{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:21:04Z","timestamp":1777062064839,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00108-023-01519-9","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:02:54Z","timestamp":1686582174000},"page":"655-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune Hepatitis","Autoimmune hepatitis"],"prefix":"10.1007","volume":"64","author":[{"given":"Jan Philipp","family":"Weltzsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annerose","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra050408","volume":"354","author":"EL Krawitt","year":"2006","unstructured":"Krawitt\u00a0EL (2006) Autoimmune hepatitis. N\u00a0Engl J Med 354:54\u201366. https:\/\/doi.org\/10.1056\/NEJMra050408","journal-title":"N Engl J Med"},{"key":"1519_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","volume":"45","author":"T Al-Chalabi","year":"2006","unstructured":"Al-Chalabi\u00a0T, Boccato\u00a0S, Portmann\u00a0BC et al (2006) Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a\u00a0large group of consecutive patients with definite AIH followed at a\u00a0tertiary referral centre. J\u00a0Hepatol 45:575\u2013583. https:\/\/doi.org\/10.1016\/j.jhep.2006.04.007","journal-title":"J Hepatol"},{"key":"1519_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/00365529850166284","volume":"33","author":"KM Boberg","year":"1998","unstructured":"Boberg\u00a0KM, Jahnsen\u00a0J, Raknerud\u00a0N, Stiris\u00a0M, Bell\u00a0H (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a\u00a0Norwegian population. Scand J Gastroenterol 33:99\u2013103. https:\/\/doi.org\/10.1080\/00365529850166284","journal-title":"Scand J Gastroenterol"},{"key":"1519_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J\u00a0Hepatol 63:971\u20131004. https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030","journal-title":"J Hepatol"},{"key":"1519_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1055\/a-1135-9306","volume":"58","author":"M Sebode","year":"2020","unstructured":"Sebode\u00a0M, Kloppenburg\u00a0A, Aigner\u00a0A et al (2020) Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Z\u00a0Gastroenterol 58:431\u2013438. https:\/\/doi.org\/10.1055\/a-1135-9306","journal-title":"Z Gastroenterol"},{"key":"1519_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"CP Strassburg","year":"2017","unstructured":"Strassburg\u00a0CP, Beckebaum\u00a0S, Geier\u00a0A et al (2017) S2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr.\u00a0021-27. Z\u00a0Gastroenterol 55:1135\u20131226. https:\/\/doi.org\/10.1055\/s-0043-120199","journal-title":"Z Gastroenterol"},{"key":"1519_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0140-6736(12)62163-1","volume":"382","author":"MA Heneghan","year":"2013","unstructured":"Heneghan\u00a0MA, Yeoman\u00a0AD, Verma\u00a0S et\u00a0al (2013) Autoimmune hepatitis. Lancet 382:1433\u20131444. https:\/\/doi.org\/10.1016\/S0140-6736(12)62163-1","journal-title":"Lancet"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","volume":"49","author":"NMF van Gerven","year":"2014","unstructured":"van Gerven\u00a0NMF, Verwer\u00a0BJ, Witte\u00a0BI et\u00a0al (2014) Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 49:1245\u20131254. https:\/\/doi.org\/10.3109\/00365521.2014.946083","journal-title":"Scand J Gastroenterol"},{"key":"1519_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","volume":"60","author":"L Gr\u00f8nb\u00e6k","year":"2014","unstructured":"Gr\u00f8nb\u00e6k\u00a0L, Vilstrup\u00a0H, Jepsen\u00a0P (2014) Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J\u00a0Hepatol 60:612\u2013617. https:\/\/doi.org\/10.1016\/j.jhep.2013.10.020","journal-title":"J Hepatol"},{"key":"1519_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2020.03.015","volume":"73","author":"J Herkel","year":"2020","unstructured":"Herkel\u00a0J, Carambia\u00a0A, Lohse\u00a0AW (2020) Autoimmune hepatitis: possible triggers, potential treatments. J\u00a0Hepatol 73:446\u2013448. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.015","journal-title":"J Hepatol"},{"key":"1519_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.autrev.2010.09.024","volume":"10","author":"LC Oliveira","year":"2011","unstructured":"Oliveira\u00a0LC, Porta\u00a0G, Marin\u00a0MLC et\u00a0al (2011) Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 10:189\u2013193. https:\/\/doi.org\/10.1016\/j.autrev.2010.09.024","journal-title":"Autoimmun Rev"},{"key":"1519_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.gastro.2005.12.020","volume":"130","author":"Y Ma","year":"2006","unstructured":"Ma\u00a0Y, Bogdanos\u00a0DP, Hussain\u00a0MJ et al (2006) Polyclonal T\u2011cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130:868\u2013882. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.020","journal-title":"Gastroenterology"},{"key":"1519_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00281-022-00937-5","volume":"44","author":"C Schulthei\u00df","year":"2022","unstructured":"Schulthei\u00df\u00a0C, Steinmann\u00a0S, Lohse\u00a0AW, Binder\u00a0M (2022) B cells in autoimmune hepatitis: bystanders or central players? Semin Immunopathol 44:411\u2013427","journal-title":"Semin Immunopathol"},{"key":"1519_CR14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0140-6736(91)92858-Y","volume":"337","author":"S Vento","year":"1991","unstructured":"Vento\u00a0S, Garofano\u00a0T, Di Perri\u00a0G et\u00a0al (1991) Identification of hepatitis A virus as a\u00a0trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337:1183\u20131187. https:\/\/doi.org\/10.1016\/0140-6736(91)92858-Y","journal-title":"Lancet"},{"key":"1519_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/s-2008-1040438","volume":"11","author":"M Manns","year":"1991","unstructured":"Manns\u00a0M (1991) Cytoplasmic autoantigens in autoimmune hepatitis: molecular analysis and clinical relevance. Semin Liver Dis 11:205\u2013214. https:\/\/doi.org\/10.1055\/s-2008-1040438","journal-title":"Semin Liver Dis"},{"key":"1519_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","volume":"40","author":"V Alla","year":"2006","unstructured":"Alla\u00a0V, Abraham\u00a0J, Siddiqui\u00a0J et\u00a0al (2006) Autoimmune hepatitis triggered by statins. J\u00a0Clin Gastroenterol 40:757\u2013761. https:\/\/doi.org\/10.1097\/00004836-200609000-00018","journal-title":"J Clin Gastroenterol"},{"key":"1519_CR17","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.jaut.2021.102741","volume":"125","author":"I Garrido","year":"2021","unstructured":"Garrido\u00a0I, Lopes\u00a0S, Sim\u00f5es\u00a0MS et al (2021) Autoimmune hepatitis after COVID-19 vaccine\u2014more than a\u00a0coincidence. J\u00a0Autoimmun 125:102741. https:\/\/doi.org\/10.1016\/j.jaut.2021.102741","journal-title":"J Autoimmun"},{"key":"1519_CR18","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.jhepr.2020.100149","volume":"2","author":"MN Rahim","year":"2020","unstructured":"Rahim\u00a0MN, Miquel\u00a0R, Heneghan\u00a0MA (2020) Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep 2:100149. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100149","journal-title":"JHEP Rep"},{"key":"1519_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","volume":"55","author":"AW Lohse","year":"2011","unstructured":"Lohse\u00a0AW, Mieli-Vergani\u00a0G (2011) Autoimmune hepatitis. J\u00a0Hepatol 55:171\u2013182. https:\/\/doi.org\/10.1016\/j.jhep.2010.12.012","journal-title":"J Hepatol"},{"key":"1519_CR20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"RJ Andrade","year":"2019","unstructured":"Andrade\u00a0RJ, Aithal\u00a0GP, Bj\u00f6rnsson\u00a0ES et al (2019) EASL clinical practice guidelines: drug-induced liver injury. J\u00a0Hepatol 70:1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"1519_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo\u00a0PY, Cohen\u00a0SM, Lim\u00a0JK (2017) ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 112:18\u201335. https:\/\/doi.org\/10.1038\/ajg.2016.517","journal-title":"Am J Gastroenterol"},{"key":"1519_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/472027","volume":"2013","author":"C Bihari","year":"2013","unstructured":"Bihari\u00a0C, Rastogi\u00a0A, Saxena\u00a0P et\u00a0al (2013) Parvovirus B19 associated hepatitis. Hepat Res Treat 2013:1\u20139. https:\/\/doi.org\/10.1155\/2013\/472027","journal-title":"Hepat Res Treat"},{"key":"1519_CR23","doi-asserted-by":"publisher","DOI":"10.3892\/mmr_00000316","author":"S Nakanishi","year":"2010","unstructured":"Nakanishi\u00a0S, Shiraki\u00a0K, Sugimoto\u00a0K et\u00a0al (2010) Clinical significance of ultrasonographic imaging of the common hepatic arterial lymph node (No. 8 LN) in chronic liver diseases. Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr_00000316","journal-title":"Mol Med Rep"},{"key":"1519_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jhep.2016.05.023","volume":"65","author":"J Hartl","year":"2016","unstructured":"Hartl\u00a0J, Denzer\u00a0U, Ehlken\u00a0H et\u00a0al (2016) Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J\u00a0Hepatol 65:769\u2013775. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.023","journal-title":"J Hepatol"},{"key":"1519_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/liv.13458","volume":"38","author":"M Sebode","year":"2018","unstructured":"Sebode\u00a0M, Hartl\u00a0J, Vergani\u00a0D, Lohse\u00a0AW (2018) Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int 38:15\u201322. https:\/\/doi.org\/10.1111\/liv.13458","journal-title":"Liver Int"},{"key":"1519_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","volume":"74","author":"J Galaski","year":"2021","unstructured":"Galaski\u00a0J, Weiler-Normann\u00a0C, Schakat\u00a0M et al (2021) Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. J\u00a0Hepatol 74:312\u2013320. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.032","journal-title":"J Hepatol"},{"key":"1519_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","volume":"9","author":"M Sebode","year":"2018","unstructured":"Sebode\u00a0M, Weiler-Normann\u00a0C, Liwinski\u00a0T, Schramm\u00a0C (2018) Autoantibodies in autoimmune liver disease\u2014clinical and diagnostic relevance. Front Immunol 9:609. https:\/\/doi.org\/10.3389\/fimmu.2018.00609","journal-title":"Front Immunol"},{"key":"1519_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/a-1364-8489","volume":"18","author":"S Steinmann","year":"2022","unstructured":"Steinmann\u00a0S, Schregel\u00a0I, Schramm\u00a0C (2022) Autoimmune Lebererkrankungen \u2013 ein Update (Teil 1). Gastroenterol Up2date 18:225\u2013241. https:\/\/doi.org\/10.1055\/a-1364-8489","journal-title":"Gastroenterol Up2date"},{"key":"1519_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.510260306","volume":"26","author":"AJ Czaja","year":"1997","unstructured":"Czaja\u00a0AJ, Morshed\u00a0SA, Parveen\u00a0S, Nishioka\u00a0M (1997) Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1\u2011autoimmune hepatitis. Hepatology 26:567\u2013572. https:\/\/doi.org\/10.1002\/hep.510260306","journal-title":"Hepatology"},{"key":"1519_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jcla.21813","volume":"30","author":"D Villalta","year":"2016","unstructured":"Villalta\u00a0D, Girolami\u00a0E, Alessio\u00a0MG et\u00a0al (2016) Autoantibody profiling in a\u00a0cohort of pediatric and adult patients with autoimmune hepatitis. J\u00a0Clin Lab Anal 30:41\u201346. https:\/\/doi.org\/10.1002\/jcla.21813","journal-title":"J Clin Lab Anal"},{"key":"1519_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/0891693021000056721","volume":"35","author":"GV Gregorio","year":"2002","unstructured":"Gregorio\u00a0GV, McFarlane\u00a0B, Bracken\u00a0P et al (2002) Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 35:515\u2013519. https:\/\/doi.org\/10.1080\/0891693021000056721","journal-title":"Autoimmunity"},{"key":"1519_CR32","doi-asserted-by":"publisher","first-page":"12662","DOI":"10.3748\/wjg.v20.i35.12662","volume":"20","author":"C Beisel","year":"2014","unstructured":"Beisel\u00a0C, Weiler-Normann\u00a0C, Teufel\u00a0A, Lohse\u00a0AW (2014) Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol 20:12662. https:\/\/doi.org\/10.3748\/wjg.v20.i35.12662","journal-title":"World J Gastroenterol"},{"key":"1519_CR33","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1093\/labmed\/lmy024","volume":"49","author":"LM Sur","year":"2018","unstructured":"Sur\u00a0LM, Floca\u00a0E, Sur\u00a0DG et\u00a0al (2018) Antinuclear antibodies: marker of diagnosis and evolution in autoimmune diseases. Lab Med 49:e62\u2013e73. https:\/\/doi.org\/10.1093\/labmed\/lmy024","journal-title":"Lab Med"},{"key":"1519_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1746-1596-4-1","volume":"4","author":"Y Kumar","year":"2009","unstructured":"Kumar\u00a0Y, Bhatia\u00a0A, Minz\u00a0RW (2009) Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a\u00a0journey revisited. Diagn Pathol 4:1. https:\/\/doi.org\/10.1186\/1746-1596-4-1","journal-title":"Diagn Pathol"},{"key":"1519_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2893.2011.01578.x","volume":"19","author":"F Girardin","year":"2012","unstructured":"Girardin\u00a0F, Daali\u00a0Y, Gex-Fabry\u00a0M et al (2012) Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. J\u00a0Viral Hepat 19:568\u2013573. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01578.x","journal-title":"J Viral Hepat"},{"key":"1519_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2013.08.001","volume":"46","author":"R Liberal","year":"2013","unstructured":"Liberal\u00a0R, Mieli-Vergani\u00a0G, Vergani\u00a0D (2013) Clinical significance of autoantibodies in autoimmune hepatitis. J\u00a0Autoimmun 46:17\u201324. https:\/\/doi.org\/10.1016\/j.jaut.2013.08.001","journal-title":"J Autoimmun"},{"key":"1519_CR37","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hep.27983","volume":"62","author":"MM Kirstein","year":"2015","unstructured":"Kirstein\u00a0MM, Metzler\u00a0F, Geiger\u00a0E et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62:1524\u20131535. https:\/\/doi.org\/10.1002\/hep.27983","journal-title":"Hepatology"},{"key":"1519_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41423-021-00768-8","volume":"19","author":"B Terziroli Beretta-Piccoli","year":"2022","unstructured":"Terziroli Beretta-Piccoli\u00a0B, Mieli-Vergani\u00a0G, Vergani\u00a0D (2022) Autoimmmune hepatitis. Cell Mol Immunol 19:158\u2013176. https:\/\/doi.org\/10.1038\/s41423-021-00768-8","journal-title":"Cell Mol Immunol"},{"key":"1519_CR39","doi-asserted-by":"publisher","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","volume":"4","author":"G Mieli-Vergani","year":"2018","unstructured":"Mieli-Vergani\u00a0G, Vergani\u00a0D, Czaja\u00a0AJ et al (2018) Autoimmune hepatitis. Nat Rev Dis Primers 4:18017. https:\/\/doi.org\/10.1038\/nrdp.2018.17","journal-title":"Nat Rev Dis Primers"},{"key":"1519_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"CP Strassburg","year":"2017","unstructured":"Strassburg\u00a0CP, Beckebaum\u00a0S, Geier\u00a0A et al (2017) S2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr.\u00a0021-27. Z\u00a0Gastroenterol 55:1135\u20131226. https:\/\/doi.org\/10.1055\/s-0043-120199","journal-title":"Z Gastroenterol"},{"key":"1519_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.mcg.0000225612.86846.82","volume":"41","author":"U Denzer","year":"2007","unstructured":"Denzer\u00a0U, Arnoldy\u00a0A, Kanzler\u00a0S et\u00a0al (2007) Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy. J\u00a0Clin Gastroenterol 41:103\u2013110. https:\/\/doi.org\/10.1097\/01.mcg.0000225612.86846.82","journal-title":"J Clin Gastroenterol"},{"key":"1519_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/BF00196814","author":"K-H Meyer zum B\u00fcschenfelde","year":"1996","unstructured":"Meyer zum B\u00fcschenfelde\u00a0K\u2011H, Dienes\u00a0H\u2011P (1996) Autoimmune hepatitis. Virchows Arch. https:\/\/doi.org\/10.1007\/BF00196814","journal-title":"Virchows Arch"},{"key":"1519_CR43","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"AW Lohse","year":"2022","unstructured":"Lohse\u00a0AW, Sebode\u00a0M, Bhathal\u00a0PS et\u00a0al (2022) Consensus recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology group. Liver Int 42:1058\u20131069. https:\/\/doi.org\/10.1111\/liv.15217","journal-title":"Liver Int"},{"key":"1519_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes\u00a0EM, Zeniya\u00a0M, Czaja\u00a0AJ et\u00a0al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169\u2013176. https:\/\/doi.org\/10.1002\/hep.22322","journal-title":"Hepatology"},{"key":"1519_CR45","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki\u00a0A, Brunt\u00a0EM, Kleiner\u00a0DE et al (2011) The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54:931\u2013939. https:\/\/doi.org\/10.1002\/hep.24481","journal-title":"Hepatology"},{"key":"1519_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","volume":"16","author":"M Peiseler","year":"2018","unstructured":"Peiseler\u00a0M, Liebscher\u00a0T, Sebode\u00a0M et al (2018) Efficacy and limitations of budesonide as a\u00a0second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 16:260\u2013267.e1. https:\/\/doi.org\/10.1016\/j.cgh.2016.12.040","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1519_CR47","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns\u00a0MP, Woynarowski\u00a0M, Kreisel\u00a0W et\u00a0al (2010) Budesonide induces remission more effectively than prednisone in a\u00a0controlled trial of patients with autoimmune hepatitis. Gastroenterology 139:1198\u20131206. https:\/\/doi.org\/10.1053\/j.gastro.2010.06.046","journal-title":"Gastroenterology"},{"key":"1519_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000183","author":"S Steinmann","year":"2023","unstructured":"Steinmann\u00a0S, Lohse\u00a0AW (2023) Treatment of autoimmune hepatitis: budesonide does not solve our problems. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000183","journal-title":"Hepatology"},{"key":"1519_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000018","author":"A D\u00edaz-Gonz\u00e1lez","year":"2023","unstructured":"D\u00edaz-Gonz\u00e1lez\u00a0A, Hern\u00e1ndez-Guerra\u00a0M, P\u00e9rez-Medrano\u00a0I et al (2023) Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000018","journal-title":"Hepatology"},{"key":"1519_CR50","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.cgh.2018.12.035","volume":"17","author":"S Pape","year":"2019","unstructured":"Pape\u00a0S, Gevers\u00a0TJG, Belias\u00a0M et\u00a0al (2019) Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 17:2068\u20132075.e2. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.035","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1519_CR51","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12879-019-4022-3","volume":"19","author":"M Honkila","year":"2019","unstructured":"Honkila\u00a0M, Niinim\u00e4ki\u00a0R, Taskinen M et al (2019) A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a\u00a0patient receiving azathioprine: a\u00a0case report and review of literature. BMC Infect Dis 19:404. https:\/\/doi.org\/10.1186\/s12879-019-4022-3","journal-title":"BMC Infect Dis"},{"key":"1519_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/gast.2002.30328","volume":"122","author":"GA Dayharsh","year":"2002","unstructured":"Dayharsh\u00a0GA, Loftus\u00a0EV, Sandborn\u00a0WJ et al (2002) Epstein-Barr virus\u2014positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6\u2011mercaptopurine. Gastroenterology 122:72\u201377. https:\/\/doi.org\/10.1053\/gast.2002.30328","journal-title":"Gastroenterology"},{"key":"1519_CR53","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","volume":"62","author":"J Hartl","year":"2015","unstructured":"Hartl\u00a0J, Ehlken\u00a0H, Weiler-Normann\u00a0C et al (2015) Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J\u00a0Hepatol 62:642\u2013646. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.018","journal-title":"J Hepatol"},{"key":"1519_CR54","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","volume":"14","author":"S H\u00fcbener","year":"2016","unstructured":"H\u00fcbener\u00a0S, Oo\u00a0YH, Than\u00a0NN et al (2016) Efficacy of 6\u2011mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol 14:445\u2013453. https:\/\/doi.org\/10.1016\/j.cgh.2015.09.037","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1519_CR55","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","volume":"73","author":"AW Lohse","year":"2020","unstructured":"Lohse\u00a0AW, Sebode\u00a0M, J\u00f8rgensen\u00a0MH et al (2020) Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group. J\u00a0Hepatol 73:1496\u20131506","journal-title":"J Hepatol"},{"key":"1519_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","volume":"76","author":"S Pape","year":"2022","unstructured":"Pape\u00a0S, Snijders\u00a0RJALM, Gevers\u00a0TJG et\u00a0al (2022) Systematic review of response criteria and endpoints in autoimmune hepatitis by the international autoimmune hepatitis group. J\u00a0Hepatol 76:841\u2013849. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.041","journal-title":"J Hepatol"},{"key":"1519_CR57","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/hep.25760","volume":"56","author":"HK Dhaliwal","year":"2012","unstructured":"Dhaliwal\u00a0HK, Anderson\u00a0R, Thornhill\u00a0EL et\u00a0al (2012) Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 56:1401\u20131408. https:\/\/doi.org\/10.1002\/hep.25760","journal-title":"Hepatology"},{"key":"1519_CR58","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/hep.26290","volume":"57","author":"JH Ngu","year":"2013","unstructured":"Ngu\u00a0JH, Gearry\u00a0RB, Frampton\u00a0CM, Stedman\u00a0CAM (2013) Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 57:2399\u20132406. https:\/\/doi.org\/10.1002\/hep.26290","journal-title":"Hepatology"},{"key":"1519_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1055\/s-2001-13708","volume":"39","author":"S Kanzler","year":"2001","unstructured":"Kanzler\u00a0S, L\u00f6hr\u00a0H, Gerken\u00a0G et al (2001) Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z\u00a0Gastroenterol 39:339\u2013348. https:\/\/doi.org\/10.1055\/s-2001-13708","journal-title":"Z Gastroenterol"},{"key":"1519_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15440","author":"E Wunsch","year":"2022","unstructured":"Wunsch\u00a0E, Krause\u00a0L, Gevers\u00a0T et al (2022) Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of \u3008scp\u3009ERN RARE-LIVER\u3008\/scp\u3009 online survey. Liver Int. https:\/\/doi.org\/10.1111\/liv.15440","journal-title":"Liver Int"},{"key":"1519_CR61","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","volume":"60","author":"C Schramm","year":"2014","unstructured":"Schramm\u00a0C, Wahl\u00a0I, Weiler-Normann\u00a0C et al (2014) Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J\u00a0Hepatol 60:618\u2013624. https:\/\/doi.org\/10.1016\/j.jhep.2013.10.035","journal-title":"J Hepatol"},{"key":"1519_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2017.11.004","volume":"68","author":"DEJ Jones","year":"2018","unstructured":"Jones\u00a0DEJ, Sturm\u00a0E, Lohse\u00a0AW (2018) Access to care in rare liver diseases: new challenges and new opportunities. J\u00a0Hepatol 68:577\u2013585. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.004","journal-title":"J Hepatol"},{"key":"1519_CR63","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-1228","author":"S Valean","year":"2019","unstructured":"Valean\u00a0S, Acalovschi\u00a0M, Dumitrascu\u00a0DL et\u00a0al (2019) Hepatocellular carcinoma in patients with autoimmune hepatitis\u2014a\u00a0systematic review of the literature published between 1989\u20132016. Med Pharm Rep. https:\/\/doi.org\/10.15386\/mpr-1228","journal-title":"Med Pharm Rep"},{"key":"1519_CR64","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis\u00a0R, Bosch\u00a0J, Garcia-Tsao\u00a0G et al (2022) Baveno VII\u2014renewing consensus in portal hypertension. J\u00a0Hepatol 76:959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01519-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:04:06Z","timestamp":1687338246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01519-9"}},"subtitle":["Von Autoantik\u00f6rpern bis Zirrhose","From autoantibodies to cirrhosis"],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01519-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>A.\u00a0Lohse:<\/b> A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: DFG, BMBF, EU, Freie und Hansestadt Hamburg. \u2013\u00a0Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: University of California, San Francisco; European Joint Program for Rare Diseases; Create4care, Essen, Zukunftssymposium Hepatologie; Falk, Vortrag Uniklinik D\u00fcsseldorf; Universit\u00e4tsklinikum Hamburg-Eppendorf.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Einzelne Konsultationen zum Studiendesign f\u00fcr neue Immunsuppressiva f\u00fcr AIH. \u2013\u00a0Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Amgen, Evotec, PerkinElmer, Roche, Fresenius.\u00a0\u2013 B. Nichtfinanzielle Interessen: Klinikdirektor, Universit\u00e4tsklinikum Hamburg-Eppendorf, I. Medizinische Klinik und Poliklinik; Kuratorium (Aufsichtsrat) des Universit\u00e4tsklinikums Hamburg-Eppendorf; Senator der DFG; Koordinator des European Reference Networks for Hepatological Diseases (ERN RARE-LIVER); Vorstand der Deutschen Gesellschaft f\u00fcr Verdauungs- und Stoffwechselkrankheiten; Vorsitzender der Arbeitsgemeinschaft Universit\u00e4rer Gastroenterologen; Vorsitzender des Kuratorium der Dr. Erich Martini Stiftung; Stifter und Vorsitzender des Stiftungsrates der YAEL Stiftung.<b>J.P.\u00a0Weltzsch:<\/b> A. Finanzielle Interessen: J. P. Weltzsch gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B. Nichtfinanzielle Interessen: Arzt in Weiterbildung im Fach Innere Medizin Schwerpunkt Gastroenterologie, I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Hamburg-Eppendorf | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), European Association of the Liver (EASL).<b>A.\u00a0Ziegler:<\/b> A. Finanzielle Interessen: A. Ziegler gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: \u00c4rztin in Weiterbildung im Fach Innere Medizin Schwerpunkt Gastroenterologie, I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Hamburg-Eppendorf | Mitgliedschaft: DGIM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}